It is known that T2D patients often overexpress PAD4, produce more NETs than non-diabetic reduced NET clearance, and mice models of T2D have increased difficulty in clearing NETs leading to decreased wound healing abilities (91). Patients treated with clarithromycin experience increased LL-37 load on NETs which enhanced wound healing and antibacterial and antiviral activity (124). The gene discussed is PADI4; the disease is type 2 diabetes mellitus.